(Brenda) B Leeneman

All publications (7)

• Article (7)

  • B. Leeneman, M.G. Franken, V. Coupe, M.P. Hendriks, W.H.J. Kruit, P. Plaisier, S. van Ruth, J. Verstijnen, M. Wouters, H.M. Blommestein & C.A. de Uyl-de Groot (2019). Stage-specific disease recurrence and survival in localized and regionally advanced cutaneous melanoma. European Journal of Surgical Oncology, 45 (5), 825-831. doi: 10.1016/j.ejso.2019.01.225
  • M.G. Franken, B. Leeneman, M. Gheorghe, C.A. Uyl - de Groot, J. Haanen & P.H.M. van Baal (2019). A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma. European Journal of Cancer, 123, 58-71. doi: 10.1016/j.ejca.2019.08.032 [go to publisher's site]
  • A. Jochems, B. Leeneman, M.G. Franken, M.G. Schouwenburg, M. Aarts, A.C.J. van Akkooi, F. van den Berkmortel, A.J.M. Van den Eertwegh, G. Groenewegen, J. de Groot, J. Haanen, G.A.P. Hospers, E. Kapiteijn, R.H. Koornstra, W.H.J. Kruit, M. Louwman, D. Piersma, R.S. van Rijn, A. ten Tije, G. Vreugdenhil, M.W.J.M. Wouters, C.A. Uyl - de Groot & J.J.M. van der Hoeven (2018). Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands. Anti-Cancer Drugs, 29 (6), 572-578. doi: 10.1097/CAD.0000000000000629
  • M.G. Franken, B. Leeneman, A. Jochems, M.G. Schouwenburg, M. Aarts, A.C.J. Akkooi, F. van den Berkmortel, A.J.M. Van den Eertwegh, J. de Groot, J.J.M. van der Hoeven, G.A.P. Hospers, E. Kapiteijn, R.H. Koornstra, W.H.J. Kruit, M. Louwman, D. Piersma, R.S. van Rijn, K. Suijkerbuijk, A. ten Tije, G. Vreugdenhil, M.W.J.M. Wouters, M. Zeijl, J. Haanen & C.A. Uyl - de Groot (2018). Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands. Anti-Cancer Drugs, 29 (6), 579-588. doi: 10.1097/CAD.0000000000000628
  • M.G. Schouwenburg, A. Jochems, B. Leeneman, M.G. Franken, A.J.M. Van den Eertwegh, J. Haanen, M.C.T. van Zeijl, M. Aarts, A.C.J. Akkooi, F. van den Berkmortel, W.A.M. Blokx, J. de Groot, G.A.P. Hospers, E. Kapiteijn, R.H. Koornstra, W.H. Kruit, M. Louwman, D. Piersma, R.S. van Rijn, K. Suijkerbuijk, A. ten Tije, G. Vreugdenhil, M. Wouters & J.J.M. van der Hoeven (2018). Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomes. Melanoma Research, 28 (4), 326-332. doi: 10.1097/cmr.0000000000000453
  • A. Jochems, M.G. Schouwenburg, B. Leeneman, M.G. Franken, A.J.M. Van den Eertwegh, J. Haanen, H. Gelderblom, C.A. de Uyl-de Groot, M. Aarts, F. van den Berkmortel, W.A.M. Blokx, M.C. Cardous-Ubbink, G. Groenewegen, J. de Groot, G.A.P. Hospers, E. Kapiteijn, R.H. Koornstra, W.H. Kruit, M. Louwman, D. Piersma, R.S. van Rijn, A. ten Tije, G. Vreugdenhil, M.W.J.M. Wouters & J.J.M. van der Hoeven (2017). Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands. European Journal of Cancer, 72, 156-165. doi: 10.1016/j.ejca.2016.11.021
  • S. de Groot, N. van der Linden, M.G. Franken, H.M. Blommestein, B. Leeneman, E.M. van Rooijen, J.J.M. van der Hoeven, M. Wouters, H.M. Westgeest & C.A. de Uyl-de Groot (2016). Balancing the optimal and the feasible: A practical guide for setting up patient registries for the collection of real-world data for health care decision making based on Dutch experiences. Value in Health. doi: 10.1016/j.jval.2016.02.007

Teaching (12)

Present position